Pulmonary hypertension in patients with sarcoidosis is associated with poor prognosis, despite treatment with a targeted therapy, according to a study published in the European Respiratory Journal.
Patients with sarcoidosis frequently develop pulmonary hypertension, which is associated with an 8- to 10-fold increase in mortality among sarcoidosis patients.
Among the 126 patients analyzed in the study, 97 received PAH-targeted therapy. Immunosuppressive therapy was either initiated or increased in 33 patients after a pulmonary hypertension diagnosis.
After four months of PAH-targeted therapy, researchers found that the pulmonary vascular resistance in patients decreased (from 9.7 to 6.9), which is directly related to a decrease in pulmonary hypertension.